Clinical trial
A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer
NCT04051827 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 23, 2019
- Completion date
- December 7, 2021
- Enrollment
- 26 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.